Protocol for a Randomized Controlled Trial Comparing Intravitreal Brolucizumab with Placebo for Chronic Central Serous Chorioretinopathy with Persistent Macular Fluid Without Choroidal Neovascular Membrane - BRICS Report #1.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Seminars in Ophthalmology Pub Date : 2025-03-28 DOI:10.1080/08820538.2025.2478072

Srishti Raksheeth Ramamurthy, Saarang Hansraj, Ritesh Narula, SriniVas R Sadda, Sobha Sivaprasad, Jay K Chhablani, Mudit Tyagi, Nikitha Gurram Reddy, Umesh Chandra Behera, Raja Narayanan

{"title":"Protocol for a Randomized Controlled Trial Comparing Intravitreal Brolucizumab with Placebo for Chronic Central Serous Chorioretinopathy with Persistent Macular Fluid Without Choroidal Neovascular Membrane - BRICS Report #1.","authors":"Srishti Raksheeth Ramamurthy, Saarang Hansraj, Ritesh Narula, SriniVas R Sadda, Sobha Sivaprasad, Jay K Chhablani, Mudit Tyagi, Nikitha Gurram Reddy, Umesh Chandra Behera, Raja Narayanan","doi":"10.1080/08820538.2025.2478072","DOIUrl":null,"url":null,"abstract":"Purpose: Established consensus is lacking for the management of chronic central serous chorioretinopathy (CSCR). The role of anti-VEGF agents in treating chronic CSCR in the absence of choroidal neovascular membrane (CNVM) is equivocal. We aim to study intravitreal brolucizumab in the treatment of persistent macular fluid in chronic CSCR without CNVM.Methods: This study is a prospective randomized, placebo-controlled trial to be conducted among 42 patients with chronic CSCR (>3 months duration) with persistent intraretinal and/or subretinal fluid. Patients will be randomized in a 1:1 ratio to receive brolucizumab or oral multivitamins. Primary endpoint will be fluid resolution on OCT at 1 and 3 months. Secondary outcome measures will include the best-corrected visual acuity, microperimetry and NEI-VFQ 25 subjective questionnaire.Conclusion: The results of this study will provide an understanding of the efficacy and safety of brolucizumab in achieving fluid resolution in chronic CSCR without CNVM.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-7"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2025.2478072","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Established consensus is lacking for the management of chronic central serous chorioretinopathy (CSCR). The role of anti-VEGF agents in treating chronic CSCR in the absence of choroidal neovascular membrane (CNVM) is equivocal. We aim to study intravitreal brolucizumab in the treatment of persistent macular fluid in chronic CSCR without CNVM.

Methods: This study is a prospective randomized, placebo-controlled trial to be conducted among 42 patients with chronic CSCR (>3 months duration) with persistent intraretinal and/or subretinal fluid. Patients will be randomized in a 1:1 ratio to receive brolucizumab or oral multivitamins. Primary endpoint will be fluid resolution on OCT at 1 and 3 months. Secondary outcome measures will include the best-corrected visual acuity, microperimetry and NEI-VFQ 25 subjective questionnaire.

Conclusion: The results of this study will provide an understanding of the efficacy and safety of brolucizumab in achieving fluid resolution in chronic CSCR without CNVM.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Ophthalmology offers current, clinically oriented reviews on the diagnosis and treatment of ophthalmic disorders. Each issue focuses on a single topic, with a primary emphasis on appropriate surgical techniques.